Skip to main content
SpringerLink
Log in

Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment

  • Portal Hypertension (JC Garcia-Pagán, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Venous thromboembolism (deep vein thrombosis and pulmonary embolism) and portal vein thrombosis (PVT) occur in up to 6.3 % and 15.9 % of patients with cirrhosis, respectively. There is recent evidence that a procoagulable prothrombotic state is related to cirrhosis despite the reduced levels of many coagulation factors, and decreased platelet counts. Indeed, (i) the combination of high levels of factor VIII, with low levels of protein C and antithrombin induces a procoagulant state in vitro; while (ii) increased levels of von Willebrand factor and decreased ADAMTS 13 activity can compensate for decreased platelet counts. PVT is partial in a majority of patients in whom it develops and may spontaneously resolve in some of them. Although PVT is associated with features of more severe liver disease, it is uncertain whether it plays a causal role in the decompensation of cirrhosis. In patients listed for liver transplantation, PVT may make the procedure difficult or impossible. Pre-transplant PVT is associated with increased post-transplant mortality rates. Studies evaluating clinical outcome of anticoagulation therapy for splanchnic or extrasplanchnic venous thrombosis are scarce. Anticoagulation therapy, given to patients with cirrhosis of intermediate severity before PVT occurrence, in prophylactic doses, appears to decrease decompensation and mortality rate. Interestingly, this improvement is out of proportion of the prophylaxis of extrahepatic portal vein thrombosis. The risk of bleeding does not seem to be increased in patients with cirrhosis receiving anticoagulation therapy, once prophylaxis for bleeding related to portal hypertension has been implemented. Overall, the room for anticoagulation therapy is probably larger than previously recognized, and may be of particular benefit in patients without portal vein thrombosis. However, clinical trials remain to be done before the benefit risk ratio of anticoagulation therapy is properly evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest. 2010;137(5):1145–9.

    Article  PubMed  Google Scholar 

  2. Manzanet G, Sanjuán F, Orbis P, et al. Liver transplantation in patients with portal vein thrombosis. Liver Transpl. 2001;7:125–31.

    Article  CAS  PubMed  Google Scholar 

  3. Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology. 2010;52(1):249–55.

    Article  CAS  PubMed  Google Scholar 

  4. Sherlock S, Alpert L. Haemorrhagic diseases in surgery. Proc R Soc Med. 1965;58(4):257–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  5. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am. 1992;6(6):1247–57.

    CAS  PubMed  Google Scholar 

  6. Muir AJ. Surgical clearance for the patient with chronic liver disease. Clin Liver Dis. 2012;16(2):421–33.

    Article  PubMed  Google Scholar 

  7. Coêlho GR, Feitosa Neto BA. de G Teixeira CC, Marinho DS, rangel ML, Garcia JH. Single-center transfusion rate for 555 consecutive liver transplantations: impact of two eras. Transplant Proc. 2013;45(9):3305–9.

    Article  PubMed  Google Scholar 

  8. Turon F, Casu S, Hernández-Gea V, Garcia-Pagán JC. Variceal and other portal hypertension related bleeding. Best Pract Res Clin Gastroenterol. 2013;27(5):649–64.

    Article  PubMed  Google Scholar 

  9. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol. 2013;59(2):265–70.

    Article  CAS  PubMed  Google Scholar 

  10. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713–23.

    Article  CAS  PubMed  Google Scholar 

  11. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147–56. Excellent Review Article concerning the most important mechanisms of the hemostatic system in cirrhosis which lead to a procoagulant environment.

    Article  CAS  PubMed  Google Scholar 

  12. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol. 2008;15(5):473–80.

    Article  PubMed  Google Scholar 

  13. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor iin cirrhosis support adhesion despite reduced functional capacity. Hepatology. 2006;44(1):53–61.

    Article  CAS  PubMed  Google Scholar 

  14. Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol. 2010;91(1):20–9.

    Article  CAS  PubMed  Google Scholar 

  15. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000;95(10):2936–9.

    Article  CAS  PubMed  Google Scholar 

  16. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121(1):131–9.

    Article  CAS  PubMed  Google Scholar 

  17. Rijken DC, Kock EL, Guimarães AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost. 2012;10(10):2116–22.

    Article  CAS  PubMed  Google Scholar 

  18. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835–46.

    Article  PubMed  Google Scholar 

  19. Burnett B. Management of venous thromboembolism. Prim Care Clin Office Pract. 2013;40:73–90.

    Article  Google Scholar 

  20. Jang MJ, Choi WI, Bang SM, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol. 2009;29(3):311–5.

    Article  CAS  PubMed  Google Scholar 

  21. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30(2):158–62.

    Article  PubMed  Google Scholar 

  22. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29(18):2276–315.

    Article  CAS  PubMed  Google Scholar 

  23. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133:381S–453.

    Article  CAS  PubMed  Google Scholar 

  24. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton 3rd LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–15.

    Article  CAS  PubMed  Google Scholar 

  25. Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006;101(7):1524–8.

    Article  PubMed  Google Scholar 

  26. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V, Forner MJ. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig. 2008;100(5):259–62.

    Article  PubMed  Google Scholar 

  27. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci. 2008;53:3012–7.

    Article  PubMed  Google Scholar 

  28. Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96–101.

    Article  PubMed  Google Scholar 

  29. Lesmana CRA, Inggriani S, Cahyadinata L, Lesmana LA. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition? Hepatol Int. 2010;4:433–8.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol. 2010;8(9):800–5.

    Article  PubMed  Google Scholar 

  31. Anthony Lizarraga W, Dalia S, Reinert SE, Schiffman FJ. Venous thrombosis in patients with chronic liver disease. Fibrinolysis. 2010;21(5):431–5.

    Article  CAS  Google Scholar 

  32. Ali M, Ananthakrishnan AN, McGinley EL, Saeian K. Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci. 2011;56:2152–59. Good cross-sectional study envolving a Nationwide sample which found a significant burden due to VTE in patients with cirrhosis.

    Article  PubMed  Google Scholar 

  33. Saleh T, Matta F, Alali F, Stein PD. Venous thromboembolism with chronic liver disease. Am J Med. 2011;124(1):64–8.

    Article  PubMed  Google Scholar 

  34. Aldawood A, Arabi Y, Aljumah A, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J. 2011;9:1.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Girleanu I, Trifan A, Cojocariu C, Singeap AM, Sfarti C, Stanciu C. The risk of thrombotic events in patients with liver cirrhosis. Rev Med Chir Soc Med Nat Lasi. 2012;116(4):991–6.

    Google Scholar 

  36. Di Minno MND, Tufano A, Rusolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol. 2010;16(48):6119–22.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Montalto G, Miceli M, Soresi M, et al. Sex hormones in patients with liver cirrhosis and hepatocellular carcinoma. Oncol Rep. 1997;4(1):173–6.

    CAS  PubMed  Google Scholar 

  38. Lustik SJ, Chhibber AK, Kolano JW, et al. The hyperventilation of cirrhosis: progesterone and estradiol effects. Hepatology. 1997;25(1):55–8.

    Article  CAS  PubMed  Google Scholar 

  39. Almeida J, Galhenage S, Yu J, Kurtovic J, Riordan SM. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol. 2006;12(10):1493–502.

    PubMed  Google Scholar 

  40. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34:32–7.

    Article  CAS  PubMed  Google Scholar 

  41. Wang X. Lipopolysaccharide augments venous and arterial thrombosis in the mouse. Thromb Res. 2008;123:355–60.

    Article  CAS  PubMed  Google Scholar 

  42. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24:1374–83.

    Article  PubMed  Google Scholar 

  43. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int. 2014;34(1):26–32. Good retrospective study, the one that shows to date that patients with cirrhosis in which thromboprophylaxis of VTE was started was not associated to high rates of complications nor death.

    Article  CAS  PubMed  Google Scholar 

  44. Gomez Cuervo C, Pardo OB, Asín MAPJ. Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis: a systematic review and meta-analysis. Thromb Res. 2013;132(4):414–19. Good meta-analysis which found heparin to be safe when used as thromboprophylaxis in patients with cirrhosis, even thaw the risk of having a VTE event was not reduced.

    Article  CAS  PubMed  Google Scholar 

  45. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37.

    Article  PubMed  Google Scholar 

  46. De Santis A, Moscatelli R, Catalano C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study. Dig Liver Dis. 2010;42(6):451–5.

    Article  PubMed  Google Scholar 

  47. Ouellette DW, Patocka C. Pulmonary embolism. Emerg Med Clin North Am. 2012;30(2):329–75.

    Article  PubMed  Google Scholar 

  48. Cage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.

    Article  Google Scholar 

  49. Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31.

    PubMed  Google Scholar 

  50. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis – possibilities and caveats. J Hepatol. 2013;59(2):358–66.

    Article  CAS  PubMed  Google Scholar 

  51. Bechmann LP, Wichert M, Kröger K, Hilgard P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int. 2011;31(7):1064. doi:10.1111/j.1478-3231.2011.02548.x.

    Article  PubMed  Google Scholar 

  52. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant. 2007;7(6):1624–8.

    Article  CAS  PubMed  Google Scholar 

  53. Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012;130:S1–3.

    Article  PubMed  Google Scholar 

  54. Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol. 2012;56(1):S25–38.

    Article  CAS  PubMed  Google Scholar 

  55. Battistelli S, Coratti F, Gori T. Porto-spleno-mesenteric venous thrombosis. Int Angiol. 2011;30(1):1–11.

    CAS  PubMed  Google Scholar 

  56. Wanless IR, Wrong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21(5):1238–47.

    CAS  PubMed  Google Scholar 

  57. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203–12. Very good review concerning the management of PVT in patients with cirrhosis undergoing liver transplantation.

    Article  PubMed  Google Scholar 

  58. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–74.

    Article  CAS  PubMed  Google Scholar 

  59. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54:691–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Nery F, Chaffaut C, Condat B, et al. Portal vein thrombosis in compensated cirrhosis: a prospective cohort study on 898 patients. Hepatology. 2013;58 Suppl 4:271A.

    Google Scholar 

  61. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40:736–41.

    Article  PubMed  Google Scholar 

  62. Belli L, Romani F, Sansalone CV, Aseni P, Rondinara G. Portal thrombosis in cirrhotics. A retrospective analysis. Ann Surg. 1986;203(3):286–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Nonami T, Yokoyama I, Iwatsuki S, Starzi TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology. 1992;16(5):1195–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology. 1985;89(2):279–86.

    CAS  PubMed  Google Scholar 

  65. Gayowski TJ, Marino IR, Doyle HR, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res. 1996;60(2):333–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Mangia A, Villani MR, Cappucci G, et al. Causes of portal venous thrombosis in cirrhotic patients : the role of genetic and acquired factors. Eur J Gastroenterol Hepatol. 2005;17:745–51.

    Article  CAS  PubMed  Google Scholar 

  67. Violi F, Ferro D, Basili S, D’Angelo A, Mazzola G, Quintarelli C, et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. Br Med J. 1994;309:239–40.

    Article  CAS  Google Scholar 

  68. Oksüzoglu G, Bayraktar Y, Arslan S, Celik I, Arslan M, Sivri B, et al. Portal vein thrombosis in cirrhotics: related with anticardiolipin antibodies? Hepatogastroenterology. 2003;50(53):1527–30.

    PubMed  Google Scholar 

  69. Mangia A, Margaglione M, Cascavilla I, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol. 1999;94(10):2983–7.

    Article  CAS  PubMed  Google Scholar 

  70. Donglei Z, Jianyu H, Ning Y. Protein C and D-dimer are related to portal tein thrombosis In patients with liver cirrhosis. J Gastroenterol Hepatol. 2010;25(1):116–21.

    Article  Google Scholar 

  71. Zhang DL, Hao JY, Yang N. Value of D-dimer and protein S for diagnosis of portal vein thrombosis in patients with liver cirrhosis. J Int Med Res. 2013;41(3):664–72.

    Article  CAS  PubMed  Google Scholar 

  72. Zocco MA, Stasio ED, Cristofaro RD, et al. Thrombotic risk factors in patients with liver cirrhosis : correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51:682–9.

    Article  PubMed  Google Scholar 

  73. Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 2000;69(9):1873–81.

    Article  CAS  PubMed  Google Scholar 

  74. Dumortier J, Czyqlik O, Poncet G, et al. Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant. 2002;2(10):934–8.

    Article  PubMed  Google Scholar 

  75. Lladó L, Fabregat J, Castellote J, et al. Management of portal vein thrombosis in liver transplantation: influence on morbidity and mortality. Clin Transplant. 2007;21(6):716–21.

    PubMed  Google Scholar 

  76. Lendoire J, Raffin G, Cejas N, et al. Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HBP (Oxford). 2007;9(5):352–6.

    Article  CAS  Google Scholar 

  77. Tao YF, Teng F, Wang ZX, et al. Liver transplant recipients with portal vein thrombosis: a single center retrospective study. Hepatobiliary Pancreat Dis Int. 2009;8(1):34–9.

    PubMed  Google Scholar 

  78. Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl. 2010;16(1):83–90.

    Article  PubMed  Google Scholar 

  79. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl. 2010;16(8):999–1005.

    Article  PubMed Central  PubMed  Google Scholar 

  80. Ravaioli M, Zanello M, Grazi GL, et al. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann Surg. 2011;253(2):378–84.

    Article  PubMed  Google Scholar 

  81. Fouzas I, Paul A, Becker C, et al. Orthotopic liver transplantation in patients with portal vein thrombosis in the absence of hepatocellular carcinoma. Transplant Proc. 2012;44(9):2734–6.

    Article  CAS  PubMed  Google Scholar 

  82. Werner KT, Sando S, Carey E, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58:1776–80. Good retrospective study involving patients evaluated for liver transplantation, demonstrating that anticoagulation treatment in the setting of PVT in these seriously ill patients is safe and effective.

    Article  CAS  PubMed  Google Scholar 

  83. John BV, Konjeti R, Aggarwal A, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12(6):952–8. Excellent longitudinal study which enrolled the highest number of patients to date showing that untreated patients with cirrhosis and PVT without anticoagulation treatment had similar outcomes than the ones without PVT before and after liver transplantation.

    CAS  PubMed  Google Scholar 

  84. Doenecke A, Tsui TY, Zuelke C, et al. Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity. Clin Transplant. 2010;24(1):48–55.

    Article  CAS  PubMed  Google Scholar 

  85. Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265(1):124–32. Very important longitudinal study focusing in the spontaneous improvement of PVT and no relationship between PVT occurrence and a worse outcome.

    Article  PubMed  Google Scholar 

  86. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–74. Good retrospective conducted study showing that PVT mostly resolves or remain unchanged without treatment without important influence on prognosis.

    Article  PubMed  Google Scholar 

  87. Nanashima A, Sumida Y, Shibasaki S, et al. Parameters associated with changes in liver volume in patients undergoing portal vein embolization. J Surg Res. 2006;133(2):95–101.

    Article  CAS  PubMed  Google Scholar 

  88. Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–60. Very good prospective study, the only one that demonstrates, to date, the efficacy of a LMWH on the prevention of PVT occurrence, decompensation of the liver disease and lower mortality rates.

    Article  CAS  PubMed  Google Scholar 

  89. DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.

    Article  CAS  PubMed  Google Scholar 

  90. Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44(6):448–51.

    CAS  PubMed  Google Scholar 

  91. Senzolo M, Sartori TM, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32(6):919–27.

    Article  CAS  PubMed  Google Scholar 

  92. Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10(7):776–83. Good retrospective study that shows efficacy and safety of anticoagulation in PVT in patients with cirrhosis, as also a non negligible percentage of rethrombosis after stopping treatment, recommending that anticoagulation should be maintained indefinitely.

    Article  PubMed  Google Scholar 

  93. Huard G, Bilodeau M. Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review. Int J Hepatol. 2012;2012:672986. doi:10.1155/2012/672986.

    Article  PubMed Central  PubMed  Google Scholar 

  94. Kerlan Jr RK, LaBerge JM, Gordon RL, Ring EJ. Transjugular intrahepatic portosystemic shunts: current status. AJR Am J Roentgenol. 1995;164(5):1059–66.

    Article  PubMed  Google Scholar 

  95. Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006;23:767–75.

    Article  CAS  PubMed  Google Scholar 

  96. Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut. 2011;60:846–52.

    Article  PubMed  Google Scholar 

  97. Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011;54(1):78–88.

    Article  PubMed  Google Scholar 

  98. Bauer J, Johnson S, Durham J, et al. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl. 2006;12(10):1544–51.

    Article  PubMed  Google Scholar 

  99. Walser EM, NcNees SW, DeLa Pena O, et al. Portal venous thrombosis: percutaneous therapy and outcome. J Vasc Interv Radiol. 1998;9:119–27.

    Article  CAS  PubMed  Google Scholar 

  100. Hrstic I, Kalauz M, Cukovic-Cavka S, Ostojic R, Banfic L, Vucelic B. Treatment of extensive subacute portal, mesenteric and ileocolic vein thrombosis with recombinant tissue plasminogen activator. Blood Coagul Fibrinolysis. 2007;18(6):581–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Dominique Valla and Filipe Nery declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Unidade de Transplante Hepato-Pancreático, Hospital Santo António, Centro Hospitalar do Porto, Oporto, Portugal

    Filipe Nery

  2. Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Oporto, Portugal

    Filipe Nery

  3. DHU UNITY, AP-HP, Hôpital Beaujon, Service d’Hépatologie, Clichy, 92110, France

    Dominique Valla

  4. Inserm, Université Paris Diderot, UMR 773-CRB3, 74018, Paris, France

    Dominique Valla

  5. Hospital Santo António, Centro Hospitalar do Porto, Largo Prof Abel Salazar S/N, 4099-001, Porto, Portugal

    Filipe Nery

  6. Hépatologie, Hôpital Beaujon, 100 boulevard Leclerc, 92118, Cichy Cédex, France

    Dominique Valla

Authors
  1. Filipe Nery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dominique Valla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Valla.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nery, F., Valla, D. Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment. Curr Hepatology Rep 13, 224–234 (2014). https://doi.org/10.1007/s11901-014-0233-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-014-0233-7

Keywords

Search

Navigation